← Back to Search

Protease Inhibitor

Group 1 - Lopinavir/Ritonavir for Coronavirus (TREATNOW Trial)

Phase 2
Waitlist Available
Led By Todd Rice, MD
Research Sponsored by Vanderbilt University Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 1 to day 29
Awards & highlights

TREATNOW Trial Summary

This trial is testing whether the drug lopinavir/ritonavir can help treat people with COVID-19 who are not in the hospital.

Eligible Conditions
  • Coronavirus
  • COVID-19

TREATNOW Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 1 to day 29
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 1 to day 29 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Modified COVID Ordinal Outcomes Scale: Study Day 15 (Group 2 and Placebo Control Group)
Secondary outcome measures
All-cause, All-location Mortality: Day 1 to Day 29 (Group 2 and Placebo Control Group)
Fever-free Days: Day 1 to Day 29 (Group 2 and Placebo Control Group)
Hospital-free Days: Day 1 to Day 29 (Group 2 and Placebo Control Group)
+9 more

TREATNOW Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: Group 1 - Lopinavir/RitonavirActive Control1 Intervention
Lopinavir/Ritonavir 400 mg/100 mg orally twice daily for twenty-eight doses (Days 1-14)
Group II: Control GroupPlacebo Group1 Intervention
Placebo unmatched orally twice daily for 14 days

Find a Location

Who is running the clinical trial?

Vanderbilt University Medical CenterLead Sponsor
857 Previous Clinical Trials
671,741 Total Patients Enrolled
AbbVieIndustry Sponsor
958 Previous Clinical Trials
501,938 Total Patients Enrolled
Todd Rice, MDPrincipal Investigator - Vanderbilt University Medical Center
Indiana University School Of Medicine (Medical School)
Vanderbilt University Medical Center (Residency)
5 Previous Clinical Trials
1,354 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
ThoraxJournal
Role of Lopinavir/ritonavir in the Treatment of SARS: Initial Virological and Clinical Findings
Chu, C M. 2004. “Role of Lopinavir/ritonavir in the Treatment of SARS: Initial Virological and Clinical Findings”. Thorax. BMJ. doi:10.1136/thorax.2003.012658.
Canadian Journal of CardiologyJournal
Guidance on Minimizing Risk of Drug-induced Ventricular Arrhythmia During Treatment of COVID-19: A Statement from the Canadian Heart Rhythm Society
Sapp, John L., Wael Alqarawi, Ciorsti J. MacIntyre, Rafik Tadros, Christian Steinberg, Jason D. Roberts, Zachary Laksman, Jeff S. Healey, and Andrew D. Krahn. 2020. “Guidance on Minimizing Risk of Drug-induced Ventricular Arrhythmia During Treatment of COVID-19: A Statement from the Canadian Heart Rhythm Society”. Canadian Journal of Cardiology. Elsevier BV. doi:10.1016/j.cjca.2020.04.003.
Cell ResearchJournal
Remdesivir and Chloroquine Effectively Inhibit the Recently Emerged Novel Coronavirus (2019-ncov) in Vitro
Wang, Manli, Ruiyuan Cao, Leike Zhang, Xinglou Yang, Jia Liu, Mingyue Xu, Zhengli Shi, Zhihong Hu, Wu Zhong, and Gengfu Xiao. 2020. “Remdesivir and Chloroquine Effectively Inhibit the Recently Emerged Novel Coronavirus (2019-ncov) in Vitro”. Cell Research. Springer Science and Business Media LLC. doi:10.1038/s41422-020-0282-0.
JamaJournal
Covid-19—new Insights on a Rapidly Changing Epidemic
del Rio, Carlos, and Preeti N. Malani. 2020. “Covid-19—new Insights on a Rapidly Changing Epidemic”. Jama. American Medical Association (AMA). doi:10.1001/jama.2020.3072.
~94 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top